Victrex’s Overweight Rating Reaffirmed at Barclays Capital (VCT)
Victrex (LON:VCT)‘s stock had its “overweight” rating reiterated by investment analysts at Barclays Capital in a note issued to investors on Friday, Analyst Ratings Net reports. They currently have a GBX 1,870 ($30.00) target price on the stock. Barclays Capital’s target price suggests a potential upside of 16.80% from the stock’s previous close.
VCT has been the subject of a number of other recent research reports. Analysts at Deutsche Bank reiterated a “buy” rating on shares of Victrex in a research note to investors on Wednesday. They now have a GBX 1,825 ($29.28) price target on the stock. Separately, analysts at JPMorgan Chase & Co. reiterated a “neutral” rating on shares of Victrex in a research note to investors on Wednesday. They now have a GBX 1,550 ($24.87) price target on the stock. Finally, analysts at Bank of America Corp. reiterated an “underperform” rating on shares of Victrex in a research note to investors on Wednesday. They now have a GBX 1,400 ($22.46) price target on the stock. Three research analysts have rated the stock with a sell rating, seven have given a hold rating and three have assigned a buy rating to the company. The stock presently has an average rating of “Hold” and an average target price of GBX 1,662.31 ($26.67).
Shares of Victrex (LON:VCT) traded down 0.19% on Friday, hitting GBX 1598.00. The stock had a trading volume of 84,293 shares. Victrex has a one year low of GBX 1366.00 and a one year high of GBX 1791.00. The stock has a 50-day moving average of GBX 1593. and a 200-day moving average of GBX 1609.. The company’s market cap is £1.345 billion.
Victrex plc is engaged in the manufacturing and selling of high performance polymers. The Company’s business is organized as two business units: Victrex Polymer Solutions (LON:VCT) and Invibio Biomaterial Solutions (Invibio).
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.